NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

VXRT

Vaxart Inc

Jul 02 • 04:00PM ET

0.4380

Dollar change -0.0218
Percentage change -4.74	%

Healthcare • Biotechnology • USA • NASD

Peers: PFE JNJ BNTX AZN MRNA GSK NVAX CVAC NVCR RLAY

| Held by: VTI VXF PRFZ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.27	Insider Own	2.70%	Shs Outstand	228.22M	Perf Week	-18.59%
Market Cap	100.00M	Forward P/E	-	EPS next Y	-0.38	Insider Trans	1.65%	Shs Float	222.15M	Perf Month	-2.67%
Enterprise Value	78.62M	PEG	-	EPS next Q	-0.09	Inst Own	18.85%	Short Float	9.53%	Perf Quarter	17.58%
Income	-58.12M	P/S	2.11	EPS this Y	15.15%	Inst Trans	-23.52%	Short Ratio	4.91	Perf Half Y	-40.07%
Sales	47.40M	P/B	2.19	EPS next Y	-35.71%	ROA	-47.02%	Short Interest	21.17M	Perf YTD	-33.85%
Book/sh	0.20	P/C	2.38	EPS next 5Y	-6.35%	ROE	-114.74%	52W High	1.07 -59.07%	Perf Year	-34.36%
Cash/sh	0.18	P/FCF	-	EPS past 3/5Y	17.05% 17.46%	ROIC	-97.52%	52W Low	0.28 53.68%	Perf 3Y	-88.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	218.06% 23.82%	Gross Margin	90.72%	Volatility	10.53% 13.40%	Perf 5Y	-93.00%
Dividend TTM	-	EV/Sales	1.66	EPS Y/Y TTM	49.04%	Oper. Margin	-120.60%	ATR (14)	0.06	Perf 10Y	-98.15%
Dividend Ex-Date	Nov 09, 2012	Quick Ratio	0.64	Sales Y/Y TTM	433.43%	Profit Margin	-122.63%	RSI (14)	42.16	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.64	EPS Q/Q	52.70%	SMA20	-14.31%	Beta	1.14	Target Price	4.67
Payout	-	Debt/Eq	0.45	Sales Q/Q	857.18%	SMA50	-5.17%	Rel Volume	0.83	Prev Close	0.46
Employees	115	LT Debt/Eq	0.31	Earnings	Jun 11 BMO	SMA200	-27.75%	Avg Volume	4.31M	Price	0.44
IPO	Mar 17, 1980	Option/Short	Yes / Yes	EPS/Sales Surpr.	27.61% 632.49%	Trades		Volume	3,590,655	Change	-4.74%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-15-24	Initiated	Oppenheimer	Outperform	$4
Dec-29-21	Resumed	Jefferies	Buy	$13 → $12
Nov-02-21	Initiated	Cantor Fitzgerald	Overweight	$15
Jun-29-21	Downgrade	B. Riley Securities	Buy → Neutral	$13 → $9
Jun-24-21	Initiated	Jefferies	Buy	$13
Jun-11-21	Initiated	Piper Sandler	Overweight	$18
Aug-12-20	Reiterated	H.C. Wainwright	Buy	$7 → $17
Jul-13-20	Initiated	B. Riley FBR	Buy	$22

Jun-30-25 06:45AM	Vicarious Surgical Announces Election of New Directors (Business Wire) -8.59%
Jun-13-25 04:52PM	Vaxart Announces Preliminary Results of Annual Meeting of Stockholders (GlobeNewswire) +30.73% -5.97%
Jun-11-25 01:02PM	Vaxart Jumps 38% After Positive Norovirus Trial (GuruFocus.com) +28.30%
07:30AM	Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology (GlobeNewswire)
Jun-10-25 04:47PM	Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial (GlobeNewswire)
04:20PM	Loading…
Jun-02-25 04:20PM	Vaxart Announces Adjournment of Annual Meeting of Stockholders (GlobeNewswire) -7.38%
May-29-25 04:05PM	Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 (GlobeNewswire) -7.32%
08:00AM	Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders (GlobeNewswire)
May-28-25 08:00AM	Vaxart Answers Additional Frequently Asked Questions from Retail Investors (GlobeNewswire)
May-27-25 08:00AM	Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial (GlobeNewswire)
May-21-25 04:45PM	Vaxart Announces Adjournment of Annual Meeting of Stockholders (GlobeNewswire) -9.98%
May-20-25 05:00PM	Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-16-25 08:00AM	Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting (GlobeNewswire) +18.99%
May-15-25 08:00AM	Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial (GlobeNewswire) +6.12%
May-14-25 04:05PM	Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine (GlobeNewswire)
03:14AM	Loading…
03:14AM	Vaxart Inc (VXRT) Q1 2025 Earnings Call Highlights: Strategic Progress Amidst Challenges (GuruFocus.com)
May-13-25 04:05PM	Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
04:01PM	Vaxart Appoints Jeroen Grasman as Chief Financial Officer (GlobeNewswire)
May-12-25 08:00AM	Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement (GlobeNewswire)
May-05-25 08:00AM	Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress (GlobeNewswire) -7.69%
May-02-25 08:00AM	Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13 (GlobeNewswire)
Apr-30-25 04:05PM	Vaxart to Present at the Citizens Life Sciences Conference (GlobeNewswire)
08:00AM	Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate (GlobeNewswire)
Apr-16-25 08:00AM	Vaxartto Present at World Vaccine Congress Washington 2025 on April 23 (GlobeNewswire)
Mar-27-25 08:00AM	Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-21-25 07:49AM	Q4 2024 Vaxart Inc Earnings Call (Thomson Reuters StreetEvents) -9.09%
03:04AM	Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ... (GuruFocus.com)
Mar-20-25 06:25PM	Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript (SeekingAlpha)
05:15PM	VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Vaxart Provides Business Update and Reports Full Year 2024 Financial Results (GlobeNewswire)
10:00AM	Loading…
10:00AM	Here are the major earnings after the close today (SeekingAlpha)
Mar-19-25 05:35PM	Vaxart FY 2024 Earnings Preview (SeekingAlpha)
Mar-13-25 08:00AM	Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20 (GlobeNewswire) -5.96%
Mar-11-25 08:00AM	Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate (GlobeNewswire)
Mar-05-25 04:05PM	Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults (GlobeNewswire)
Jan-28-25 08:00AM	Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors (GlobeNewswire)
Jan-14-25 08:00AM	Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs (GlobeNewswire)
Jan-13-25 07:55PM	Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial (GlobeNewswire) -8.81%
Dec-28-24 09:30AM	Vaxart project agreement change ups funding for oral COVID vaccine candidate (TipRanks)
Dec-02-24 04:01PM	Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate (GlobeNewswire)
Nov-19-24 08:00AM	Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-24 02:14AM	Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and ... (GuruFocus.com) -11.80%
Nov-13-24 05:20PM	VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-07-24 08:00AM	Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13 (GlobeNewswire)
Oct-24-24 08:00AM	Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024 (GlobeNewswire)
Oct-15-24 08:00AM	Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need (GlobeNewswire)
Oct-09-24 05:52PM	Vaxart Inc (VXRT) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Advances (GuruFocus.com)
Sep-30-24 04:12PM	Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate (GlobeNewswire)
Aug-30-24 08:00AM	Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-24 08:00AM	Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia (GlobeNewswire)
Aug-15-24 01:57PM	Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside (Benzinga) +25.66%
Aug-09-24 11:48AM	Q2 2024 Vaxart Inc Earnings Call (Thomson Reuters StreetEvents) -7.95%
Aug-08-24 09:59PM	VXRT Stock Earnings: Vaxart Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace) +5.74%
05:30PM	VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-02-24 08:00AM	Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8 (GlobeNewswire) -5.95%
Jun-17-24 04:05PM	Vaxart Provides Business Update (GlobeNewswire) -8.25% +30.16%
Jun-14-24 10:06AM	Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering (Benzinga) -23.67%
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-13-24 07:07PM	Vaxart Announces $40 Million Underwritten Offering of Common Stock (GlobeNewswire)
04:15PM	Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate (GlobeNewswire)
May-23-24 04:01PM	Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.46%
May-14-24 01:07PM	Q1 2024 Vaxart Inc Earnings Call (Thomson Reuters StreetEvents) +5.45%
08:20AM	Vaxart, Inc. (NASDAQ:VXRT) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:07AM	Vaxart Inc (VXRT) Q1 2024 Earnings Call Transcript Highlights: Promising Developments and ... (GuruFocus.com)
May-13-24 08:56PM	VXRT Stock Earnings: Vaxart Meets EPS, Beats Revenue for Q1 2024 (InvestorPlace) +16.31%
04:01PM	Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 08:00AM	Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13 (GlobeNewswire)
Apr-30-24 08:00AM	Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers (GlobeNewswire)
Apr-09-24 04:30PM	Election Year Encore: Can 2020s Top 7 Stock Winners Repeat Their Performance in 2024? (InvestorPlace)
Mar-27-24 08:00AM	Vaxart to Present at World Vaccine Congress Washington 2024 on April 3 (GlobeNewswire) +5.74%
Mar-20-24 08:00AM	Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.90%
Mar-15-24 01:45PM	Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:33AM	Q4 2023 Vaxart Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-14-24 08:55PM	VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
05:35PM	Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results (GuruFocus.com)
04:01PM	Vaxart Provides Business Update and Reports Full Year 2023 Financial Results (GlobeNewswire)
Mar-07-24 08:00AM	Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14 (GlobeNewswire) -7.50%
Mar-06-24 08:00AM	Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director (GlobeNewswire)
Feb-26-24 12:00PM	VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-20-24 09:55AM	VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Feb-05-24 08:00AM	Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge (GlobeNewswire)
Jan-19-24 08:30AM	Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate (GlobeNewswire) -6.59%
Jan-16-24 09:25AM	Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management (GlobeNewswire) +29.41%
09:22AM	Vaxart, Inc. Announces Management Change (GlobeNewswire)
Dec-21-23 08:00AM	Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers (GlobeNewswire)
Nov-03-23 11:47AM	Vaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.09%
Nov-02-23 06:39PM	Vaxart Inc (VXRT) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:01PM	Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
08:00AM	Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers (GlobeNewswire)
Oct-26-23 08:00AM	Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2 (GlobeNewswire)
Oct-11-23 08:00AM	Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19 (GlobeNewswire)
Sep-21-23 08:00AM	Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-12-23 12:48PM	3 Biotech Blockbusters to Turn $5,000 Into $50,000 (InvestorPlace)
Sep-06-23 04:05PM	Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate (GlobeNewswire) -8.00%
Aug-15-23 01:46PM	Bears are Losing Control Over VAXART, INC. (VXRT), Here's Why It's a 'Buy' Now (Zacks)
Aug-05-23 06:39AM	Vaxart, Inc. (NASDAQ:VXRT) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 05:15PM	VAXART, INC. (VXRT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded by Sean Tucker in March 2004 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lee Phillip E (VXRT)	Former Executive Officer	May 27 '25	Proposed Sale	0.46	81,364	37,427		May 27 08:30 PM
Lo Steven	President, Chief Exec Officer	May 19 '25	Buy	0.49	100,000	49,000	100,000	May 19 06:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VXRT

Vaxart Inc

Upgrade your FINVIZ experience